Your browser doesn't support javascript.
loading
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André, F; Ciruelos, E M; Juric, D; Loibl, S; Campone, M; Mayer, I A; Rubovszky, G; Yamashita, T; Kaufman, B; Lu, Y-S; Inoue, K; Pápai, Z; Takahashi, M; Ghaznawi, F; Mills, D; Kaper, M; Miller, M; Conte, P F; Iwata, H; Rugo, H S.
Afiliação
  • André F; Department of Medical Oncology, Institut Gustave Roussy, Villejuif and Paris Saclay University, Orsay, France. Electronic address: Fabrice.ANDRE@gustaveroussy.fr.
  • Ciruelos EM; Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Juric D; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, USA.
  • Loibl S; Department of Medicine and Research, German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany.
  • Campone M; Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, Nantes Cedex, France.
  • Mayer IA; Hematology/Oncology, Vanderbilt University, Nashville, USA.
  • Rubovszky G; Department of Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary.
  • Yamashita T; Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan.
  • Kaufman B; Medical Oncology, Tel Aviv University, Sheba Medical Centre, Tel Hashomer, Israel.
  • Lu YS; Medical Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Inoue K; Breast Surgery, Saitama Cancer Center, Saitama, Japan.
  • Pápai Z; Medical Oncology, Hungarian Defence Forces Medical Centre, Budapest, Hungary.
  • Takahashi M; Breast Surgery, NHO Hokkaido Cancer Center, Sapporo, Japan.
  • Ghaznawi F; Novartis Pharmaceuticals Corporation, East Hanover, USA.
  • Mills D; Novartis Pharma AG, Basel, Switzerland.
  • Kaper M; Novartis Pharmaceuticals Corporation, East Hanover, USA.
  • Miller M; Novartis Pharmaceuticals Corporation, East Hanover, USA.
  • Conte PF; Medical Oncology, Universita di Padova and Oncologia Medica 2, Istituto Oncologico Veneto IRCCS, Padua, Italy.
  • Iwata H; Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
  • Rugo HS; Breast Department, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
Ann Oncol ; 32(2): 208-217, 2021 02.
Article em En | MEDLINE | ID: mdl-33246021
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article